

1635
Box 500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 13 2003

TECH CENTER 1600/2900

In re Application of:

Gerhard Siemeister et al.

:

Serial No.: 09/887,527

:

Art Unit: 1635

#12/K.T.

Filed: June 25, 2001

:

Examiner: J. Eric Angell

2/13

For: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH
VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND
THEIR USE

Seq. /
C.

PRELIMINARY AMENDMENT

continued
in-part

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Prior to initial examination and in reply to the Notice to Comply mailed January 9, 2003, please amend the above identified-application as follows:

IN THE SPECIFICATION

Please amend page 15, lines 21-25 as follows:

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a 60 are of main interest.

IN THE CLAIMS:

Please amend claim 13 as follows:

13. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/or II ~~Seq ID Nos. 34a~~ SEQ ID NO:60.

O.K.
to enter
8-29-03

N.K.

N.K.